"Eric Benjamin from Insulet discusses advancements in insulin delivery systems controlled by automation"
Insulet's Hybrid Closed-Loop Systems and AID Systems for Type 2 Diabetes
Insulet, a leading player in automated insulin delivery (AID) systems, is continuing to innovate and maintain its market leadership by focusing on Type 2 diabetes (T2D) patients. The company's Omnipod insulin delivery system, including its automated insulin delivery features, is already indicated for both Type 1 and Type 2 diabetes and is available as of mid-2025.
Hybrid closed-loop systems, such as the Omnipod 5, are currently being used by some T2D patients. These systems, which include features like mealtime insulin dose calculations, exercise flagging, and manual adjustments, have shown promising results in improving glucose control compared to traditional pump and sensor therapy. However, while these systems are available, randomized controlled trials specifically confirming their efficacy in T2D remain limited or ongoing.
Insulet recently received an expanded indication from the Food and Drug Administration for its Omnipod 5 automated insulin delivery system for people with Type 2 diabetes. The company presented the new analysis of its SECURE-T2D pivotal trial at the American Diabetes Association's Scientific Sessions this weekend, which showed that the Omnipod 5 system reduced users' diabetes distress over 13 weeks.
Insulet is also developing new AID systems, including a next generation hybrid closed loop system and a fully closed loop system. The company plans to begin its second set of EVOLUTION studies for a closed-loop system for people with Type 2 diabetes in the second half of this year.
However, fully closed-loop systems for T2D are still in the clinical trial stage and not widely commercially released. These systems have been tested safely and effectively for hospitalized patients with T2D, but broad outpatient availability is limited by practical challenges such as device procurement, clinical integration, and reimbursement details.
Insulet's focus on T2D for its hybrid closed loop systems is due to the lower risk of hypoglycemia compared to Type 1 diabetes. The company is also facing competition from other companies such as Tandem, Medtronic, and Beta Bionics, which are also developing their own patch pumps. However, Insulet's CEO, Ashley McEvoy, views this as a form of flattery.
According to Insulet's chief product and customer experience officer, Eric Benjamin, more than 30% of new patient starts in the first quarter of 2025 were people with Type 2 diabetes. This demonstrates a growing market for AID systems in T2D management.
In summary, hybrid closed-loop AID systems are available and used by some T2D patients in 2025, while fully closed-loop systems for T2D are still in the clinical trial stage and not widely commercially released. Insulet's focus on T2D and its recent expansion into the market for T2D patients with its Omnipod 5 system is a promising development in the management of T2D.
Key points: - Insulet's Omnipod 5 system is now indicated for Type 2 diabetes and is available. - Hybrid closed-loop systems are being used by some T2D patients, but randomized controlled trials are still ongoing. - Insulet is developing new AID systems, including a next generation hybrid closed loop system and a fully closed loop system. - Fully closed-loop systems for T2D are still in the clinical trial stage and not widely commercially released. - Insulet's focus on T2D and its recent expansion into the market for T2D patients with its Omnipod 5 system is a promising development in the management of T2D.
- Insulet, a medtech company, is focusing on Type 2 diabetes patients with their automated insulin delivery (AID) systems, such as the Omnipod 5, which is now indicated for T2D and available from mid-2025.
- Hybrid closed-loop systems like the Omnipod 5 are currently being used by some T2D patients, offering features like mealtime insulin dose calculations, exercise flagging, and manual adjustments, to improve glucose control.
- Insulet recently received an expanded indication for their Omnipod 5 system from the FDA, and data from the SECURE-T2D pivotal trial presented at the American Diabetes Association's Scientific Sessions showed that the system reduced users' diabetes distress over 13 weeks.
- Insulet is also developing new AID systems, including a next generation hybrid closed loop system and a fully closed loop system, moving forward with EVOLUTION studies in the second half of 2025.
- While fully closed-loop systems for T2D are still in clinical trials, they have been tested safely and effectively for hospitalized T2D patients, with commercial release limited by practical challenges.
- Insulet's CEO, Ashley McEvoy, views competition from other companies such as Tandem, Medtronic, and Beta Bionics as a form of flattery in the growing medical-conditions and health-and-wellness market.
- More than 30% of new patient starts in the first quarter of 2025 were people with Type 2 diabetes, demonstrating a growing demand for AID systems in managing chronic diseases like Type 2 diabetes.
- As more devices enter the fitness-and-exercise, nutrition, and technology landscape, Insulet's focus on Type 2 diabetes with their Omnipod 5 system remains a promising development for improving diabetes management and patient analytics in this evolving medtech news and earnings environment, including M&A and AI advancements in science.
